In short
Tazarotene is a synthetic retinoid medication that has been extensively studied in clinical trials for various dermatological conditions. This powerful topical treatment works by normalizing skin cell growth and reducing inflammation. Clinical trials have investigated tazarotene in different formulations (creams, gels, foams, and lotions) and concentrations (primarily 0.05% and 0.1%) for conditions including acne vulgaris, plaque psoriasis, and other skin disorders. This article examines the evidence from clinical trials regarding tazarotene's effectiveness, safety profile, and application methods to help patients better understand this treatment option.
Key points
- Clinical trials have extensively studied tazarotene, a synthetic retinoid, for multiple skin conditions, with acne vulgaris and plaque psoriasis being the most common targets. Available in cream, gel, foam, and lotion formulations at concentrations ranging from 0.045% to 0.1%, tazarotene works by normalizing skin cell differentiation and reducing inflammation. Studies consistently show it reduces both inflammatory and non-inflammatory acne lesions and improves overall skin appearance when compared to placebo controls. While effective, tazarotene commonly causes local skin reactions including dryness, peeling, redness, and burning/stinging sensations. New formulations like short-contact applications (applied for just one minute then rinsed off) aim to maintain efficacy while reducing irritation.
At a glance
- Primary Conditions Studied
- Acne vulgaris (most common); Plaque psoriasis; Basal cell skin cancer/nevus syndrome; Brittle nails; Cutaneous T-cell lymphoma; Post-inflammatory erythema and hyperpigmentation; Atrophic acne scars
- Formulations Tested
- Cream (0.05% and 0.1%); Gel (0.05% and 0.1%); Foam (0.1%); Lotion (0.045% and 0.1%)
- Application Methods
- Most formulations: Once daily (often in the evening); DFD-03 Lotion: Twice daily, applied for 1 minute then rinsed off; For acne: Applied to entire face; For psoriasis: Applied only to affected lesions
- Efficacy Measurements
- Reduction in inflammatory and non-inflammatory lesion counts; Improvement in Investigator's Global Assessment (IGA) scores; For psoriasis: Improvement in Psoriasis Area Severity Index (PASI); Subject satisfaction and quality of life measures
- Common Side Effects
- Erythema (redness); Dryness; Peeling; Burning or stinging sensation; Itching
- Comparative Studies
- Tazarotene vs. adapalene for acne; Tazarotene + dapsone vs. tazarotene alone for acne; Tazarotene vs. microneedling for acne scars; Different formulations compared for local tolerability
- Special Applications
- Low concentration (0.045%) for sensitive skin; Short-contact application (1 minute) for reduced irritation; Oral form (GRI-0621) being studied for idiopathic pulmonary fibrosis; Used as a preventative treatment for hand-foot skin reactions during cancer therapy
What is Tazarotene?
Tazarotene is a prescription medication that belongs to a class of drugs known as retinoids, which are related to vitamin A. Specifically, it is classified as an acetylenic retinoid, which means it has a particular chemical structure that makes it effective for certain skin conditions. Tazarotene is available under various brand names, including Tazorac®, Fabior™, and Arazlo™, among others .
How Does Tazarotene Work?
Tazarotene works by normalizing skin cell development and reducing inflammation. When applied to the skin, tazarotene is converted to its active form, tazarotenic acid, which then binds to specific receptors in skin cells. This binding action helps to:
- Normalize the way skin cells grow and develop
- Reduce the influx of inflammatory cells into the skin
- Promote the shedding of dead skin cells, preventing pore blockage
- Stimulate collagen production, which may help with certain types of scarring
By affecting these processes, tazarotene can help manage various skin conditions characterized by abnormal skin cell growth or inflammation .
Conditions Treated with Tazarotene
Clinical trials have shown that tazarotene is effective in treating several skin conditions:
Acne Vulgaris
Acne vulgaris is a common skin condition characterized by comedones (blackheads and whiteheads), inflammatory lesions (papules, pustules, and nodules), and sometimes scarring. Tazarotene has been extensively studied for treating moderate to severe acne .
Plaque Psoriasis
Plaque psoriasis is a chronic autoimmune condition characterized by raised, red, scaly patches on the skin. Tazarotene helps reduce the thickness, scaling, and redness of psoriatic plaques .
Other Skin Conditions
Clinical trials have also investigated tazarotene for treating:
- Basal cell carcinoma (BCC) and basal cell nevus syndrome (BCNS): Studies have examined tazarotene's potential as a chemopreventive agent for these conditions .
- Brittle nails: Tazarotene may help improve the condition of brittle fingernails .
- Atrophic post-acne scarring: Research suggests tazarotene might help improve the appearance of acne scars .
- Cutaneous T-cell lymphoma: Tazarotene has been studied as a treatment for this rare type of skin cancer .
- Hand-foot skin reaction (HFSR): Tazarotene may help prevent this side effect from certain cancer medications .
- Postinflammatory erythema (PIE) and postinflammatory hyperpigmentation (PIH): These are skin discolorations that can occur after acne heals .
- Nail psoriasis: Tazarotene has been studied for treating psoriasis affecting the nails .
Formulations and Strengths
Tazarotene is available in several formulations and strengths, allowing for tailored treatment approaches based on the condition being treated and individual patient factors:
- Cream: Available in 0.05% and 0.1% strengths
- Gel: Available in 0.05% and 0.1% strengths
- Foam: Available in 0.1% strength
- Lotion: Available in 0.045% and 0.1% strengths
Lower concentrations (0.045% or 0.05%) are often used for more sensitive skin or milder conditions, while higher concentrations (0.1%) may be prescribed for more severe cases .
Application Methods
How tazarotene is applied depends on the formulation and the specific condition being treated:
For Acne Vulgaris
- Apply a thin layer to clean, dry skin once daily, typically in the evening
- Some formulations (like DFD-03 lotion) may be applied twice daily for 1 minute and then rinsed off
- Treatment areas typically include the entire face, avoiding the eyes, lips, and mucous membranes
- Some patients may also apply to other affected areas such as the chest, back, and shoulders
For Plaque Psoriasis
- Apply a thin film to cover only the affected areas once daily
- Avoid application to unaffected skin
- Follow your doctor's instructions regarding how long to leave the medication on
Your healthcare provider will give you specific instructions based on your condition, the formulation prescribed, and your individual skin characteristics .
Efficacy in Treating Acne Vulgaris
Multiple clinical trials have demonstrated the effectiveness of tazarotene for acne vulgaris:
Impact on Acne Lesions
Studies show that tazarotene significantly reduces both inflammatory lesions (papules, pustules, and nodules) and non-inflammatory lesions (open and closed comedones) in patients with acne. In clinical trials, patients typically experienced:
- Significant reduction in inflammatory lesion counts after 12 weeks of treatment
- Significant reduction in non-inflammatory lesion counts after 12 weeks of treatment
- Continued improvement with longer treatment duration
Global Assessment Improvement
Many patients achieve a clinical response of "success," defined as an Investigator's Global Assessment (IGA) score that is at least two grades less than the baseline assessment. This means their acne severity improved substantially during treatment .
Comparative studies have shown that tazarotene is effective in various formulations (cream, gel, foam, lotion), with newer formulations designed to minimize irritation while maintaining efficacy .
Efficacy in Treating Plaque Psoriasis
Tazarotene has demonstrated efficacy in treating plaque psoriasis in clinical studies:
Treatment Success Rates
In clinical trials, treatment success for psoriasis was defined as achieving a score of 0 (clear), 1 (minimal), or 2 (mild disease) on the Investigator's Global Assessment (IGA) scale. Many patients achieved this level of improvement after 12 weeks of treatment .
Improvement in Psoriatic Features
Tazarotene helps improve specific features of psoriatic plaques:
- Reduction in plaque elevation (thickness)
- Decrease in scaling
- Lessening of erythema (redness)
These improvements are measured using the Psoriasis Area Severity Index (PASI), with many patients achieving scores of 1 or less (indicating clear or almost clear) for these parameters after treatment .
Efficacy in Other Skin Conditions
Basal Cell Carcinoma and Basal Cell Nevus Syndrome
Research suggests that tazarotene may help as a chemopreventive agent for basal cell carcinomas (BCCs) in patients with basal cell nevus syndrome (BCNS). In one study, topical tazarotene was applied over 18 months, and researchers evaluated whether it reduced the incidence of BCCs on treated skin .
Brittle Nails
In a study of tazarotene for brittle nails, patients applied the medication twice daily to affected fingernails for 24 weeks. Improvements were measured in roughness, raggedness, and peeling of the nails .
Atrophic Post-Acne Scarring
Clinical research has compared tazarotene to other treatments like microneedling for atrophic post-acne scars. Some studies suggest that daily application of tazarotene gel 0.1% may help improve the appearance of certain types of acne scars .
Postinflammatory Erythema and Hyperpigmentation
Tazarotene is being studied for its potential to treat postinflammatory erythema (skin reddening) and postinflammatory hyperpigmentation (dark spots) that can occur after acne lesions heal. The lower concentration formulation (0.045%) may be beneficial in reducing these discolorations with less irritation than higher concentrations .
Potential Side Effects
As with any medication, tazarotene can cause side effects. Common side effects include:
Local Skin Reactions
- Erythema (redness): May range from slight to moderate
- Dryness: The skin may become dry with continued use
- Peeling: Mild to moderate peeling of the skin is common
- Burning or stinging: Especially when first applied
- Itching: May occur in the treatment area
These side effects are typically most pronounced during the first few weeks of treatment and often decrease over time as your skin adjusts to the medication .
Less Common Side Effects
- Skin irritation
- Contact dermatitis
- Temporary worsening of acne or psoriasis initially
- Increased sensitivity to sunlight
If you experience severe irritation or an allergic reaction, discontinue use and contact your healthcare provider immediately .
Special Considerations
Sun Sensitivity
Tazarotene can make your skin more sensitive to sunlight. To protect your skin:
- Limit sun exposure, especially between 10 AM and 2 PM
- Use broad-spectrum sunscreen with SPF 30 or higher
- Wear protective clothing, hats, and sunglasses
- Avoid tanning beds and sunlamps
Pregnancy and Breastfeeding
Tazarotene is classified as pregnancy category X, meaning it should not be used during pregnancy as it may cause birth defects. Women of childbearing potential should use effective contraception during treatment. Discuss with your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding .
Combination Therapy
Tazarotene is sometimes used in combination with other treatments for enhanced effectiveness:
- For acne, it may be combined with topical antibiotics or benzoyl peroxide
- For psoriasis, it may be used alongside corticosteroids or phototherapy
Your healthcare provider will determine the most appropriate treatment approach for your specific condition .
New Research Applications
Ongoing research is exploring new potential uses for tazarotene:
- Treatment of idiopathic pulmonary fibrosis (IPF) with an oral formulation (GRI-0621)
- Prevention of hand-foot skin reaction in cancer patients receiving certain medications
- Treatment of postinflammatory pigmentation changes following acne
These applications are still being investigated in clinical trials and are not yet approved for routine clinical use .